 | • レポートコード：MRC2303K053 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界のギランバレー症候群（GBS）市場規模が、予測期間中（2022年-2027年）、CAGR 5.2％で増大すると予測されています。本レポートでは、ギランバレー症候群（GBS）の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療種類別（静注用免疫グロブリン製剤、血漿交換、その他）分析、投与経路別（経口、非経口）分析、流通チャネル別（病院内薬局、小売薬局、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、CSL Limited、Takeda Pharmaceutical Company Limited、Grifols S A、Octapharma AG、Bayer AG、Kedrion Biopharma Inc、China Biologic Products Holdings Inc、Biotest AG、Annexon Inc.、Cellenkos inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のギランバレー症候群（GBS）市場規模：治療種類別 - 静注用免疫グロブリン製剤の市場規模 - 血漿交換の市場規模 - その他ギランバレー症候群（GBS）の市場規模 ・世界のギランバレー症候群（GBS）市場規模：投与経路別 - 経口型ギランバレー症候群（GBS）の市場規模 - 非経口型ギランバレー症候群（GBS）の市場規模 ・世界のギランバレー症候群（GBS）市場規模：流通チャネル別 - 病院内薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 - その他チャネルの市場規模 ・世界のギランバレー症候群（GBS）市場規模：地域別 - 北米のギランバレー症候群（GBS）市場規模 アメリカのギランバレー症候群（GBS）市場規模 カナダのギランバレー症候群（GBS）市場規模 メキシコのギランバレー症候群（GBS）市場規模 … - ヨーロッパのギランバレー症候群（GBS）市場規模 ドイツのギランバレー症候群（GBS）市場規模 イギリスのギランバレー症候群（GBS）市場規模 フランスのギランバレー症候群（GBS）市場規模 … - アジア太平洋のギランバレー症候群（GBS）市場規模 中国のギランバレー症候群（GBS）市場規模 日本のギランバレー症候群（GBS）市場規模 インドのギランバレー症候群（GBS）市場規模 … - 南米/中東のギランバレー症候群（GBS）市場規模 南アフリカのギランバレー症候群（GBS）市場規模 ブラジルのギランバレー症候群（GBS）市場規模 アルゼンチンのギランバレー症候群（GBS）市場規模 … ・競争状況 ・市場機会・将来動向 |
The Guillain-Barre Syndrome Market studied is anticipated to grow at a CAGR of 5.2% during the forecast period, 2022-2027.
The Guillain-Barre syndrome (GBS) market was significantly impacted by COVID-19. Patients with Guillain-Barre syndrome were advised to take extra precautions to minimize the risk of getting COVID-19. Moreover, Guillain-Barre syndrome patients may not show typical symptoms such as a high temperature, and they may also experience a higher-than-normal pain threshold, which may delay the diagnosis of COVID-19. Furthermore, the article titled “Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study” published in Oxford Academic in September 2021, suggested that a COVID-19 infection may cause Guillain-Barré syndrome. The article further detailed that from January 30 to May 30, 2020, researchers analyzed individuals as part of the International GBS Outcome Study (or IGOS), a global cohort of individuals with Guillain-Barré syndrome. During this time, the study included an additional 49 Guillain-Barré syndrome patients from China, Denmark, France, Greece, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom. In this cohort analysis, 22% of the Guillain-Barré syndrome patients had a preceding COVID-19 infection in the first 4 months of the pandemic. Such studies greatly highlighted the need for diagnosis and treatment of GBS, thereby boosting the market’s growth over the pandemic phase.
Furthermore, the major factors contributing to the growth of the studied market are the increasing geriatric population, the growing prevalence of GBS, and product approval due to accelerated drug developments.
The rise in the geriatric population propels market growth over the forecast period. For instance, according to the World Health Organization’s 2021 updates, by 2030, 1 out of every 6 people across the globe will be 60 years old or older. The number of people aged 60 and up is expected to rise from 1 billion in 2020 to 1.4 billion by 2050. By 2050, the global population of people aged 60 and above will get doubled to reach 2.1 billion. Between 2020 and 2050, the number of people aged 80 and above is expected to triple, reaching 426 million. Furthermore, according to the study titled “Global, regional, and national burden of Guillain–Barré syndrome and its underlying causes from 1990 to 2019” published in the Journal of Neuroinflammation in November 2021, with growing age, the age-standardized burden of GBS increased and was higher in males across all age categories. The article provided first in-depth investigation of the prevalence and disability burden of Guillain-Barré syndrome (GBS) from 1990 to 2019 by cause, age, sex, and socio-demographic index (SDI) in 204 countries and territories. Thus, such instances are likely to propel the market’s growth over the coming years.
In addition, the rise in new product approvals due to the accelerated drug approval initiative by the United States Food and Drug Administration is also boosting the market growth. For instance, in September 2019, Annexon Biosciences revealed that the United States Food and Drug Administration had granted fast-track designation to ANX005, a novel treatment for Guillain-Barré syndrome.
Thus, the aforesaid factors are likely to boost the growth of the market over the forecast period. However, higher challenges in the development stage, expensive patented products, and lack of awareness of the disease and effective treatment in the developing economies are the major restraining factors for the market studied.
Guillain Barre Syndrome Market Trends
Intravenous Immunoglobulin Segment is Expected to Hold the Large Market Share Over the Forecast Period
Intravenous immunoglobulin (IVIG) therapy is the use of a mixture of antibodies (immunoglobulins) to treat health conditions, including primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS, measles, Guillain-Barré syndrome, and certain other infections. Depending on the formulation, it can be injected into the muscle, a vein, or under the skin.
Intravenous immunoglobulins are expected to account for a large share of the market, which can be attributed to the availability of a wide range of IVIG products such as Gamunex, Gammagard, and Privigen in the market and increased adoption of treatment by off-label use of intravenous immunoglobulins due to the rising prevalence of multifocal motor neuropathy, dermatomyositis, polymyositis, stiff person syndrome, and relapsing-remitting multiple sclerosis. Furthermore, according to the Centers for Disease Control and Prevention, June 2022 update, GBS affects about 3,000–6,000 people each year in the United States. Such a burden of disease is fueling the demand for effective treatment, which is expected to drive the growth of the market segment over the forecast period.
In addition, increasing research studies for intravenous immunoglobulin (IVIG) are also expected to boost the growth of the market segment. For instance, in November 2021, the study titled “Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome” an interventional clinical trial by Assiut University is expected to be completed by December 2022. Such clinical studies may lead to the development of a newer products in the future and thus are expected to drive the growth of the market segment.
Thus, all the aforementioned factors are expected to boost segment growth over the forecast period.
North America Dominates the Market and Expected to do Same Over the Forecast Period.
North America is expected to dominate the overall GBS market throughout the forecast period. The dominance is due to several factors, such as the increasing geriatric population with higher chances of acquiring GBS, the presence of major market players, and growing awareness regarding GBS within the population.
According to the Centers for Disease Control and Prevention (CDC) article updated in June 2022, infection with Campylobacter jejuni, which causes diarrhea, is one of the most common causes of GBS. It also reported that people of any age group can develop GBS, but the risk of GBS increases in people aged over 50 years. Additionally, as per the Statistics Canada 2021 census, there were around 7,021,430 people aged 65 years or above, out of which 3,224,680 were males and 3,796,750 were females. Such an increase in the geriatric population coupled with the high risk of acquiring GBS is expected to boost the market’s growth in the near future.
Moreover, the funding from public organizations for the different projects related to the GBS is expected to boost the growth of the market in North America. For instance, in October 2021, the National Institute of Neurological Disorders and Stroke (NINDS) approved USD 427,625 funding for co-investigators Brad Wright, Ph.D., Rebecca Traub, MD, and Chip Howard, MD for the project dealing with the understanding of Guillain-Barre syndrome using medicare claims and is expected to be completed by February 2023.
Thus, owing to the abovementioned factors, the studied market in the North American region is expected to boost the growth of the market.
Guillain Barre Syndrome Market Competitor Analysis
The Guillain-Barre Syndrome market is moderately competitive and consists of several major players. Various strategies, such as the acquisition of the products by other companies, consolidate the market positions across the globe. Some of the companies currently dominating the market are Grifols S.A., CSL Limited, Octapharma AG, Kedrion Biopharma Inc., and Takeda Pharmaceutical Company Limited, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Prevalence of GBS and Geriatric Population
4.2.2 Rise in New Product Approvals due to Accelerated Drug Approval Initiative by USFDA
4.3 Market Restraints
4.3.1 Higher Challenges in Development Stage and Expensive Patented Products
4.3.2 Lack of Awareness of Disease and Effective Treatment in the Developing Economies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Therapeutics
5.1.1 Intravenous Immunoglobulin
5.1.2 Plasma Exchange
5.1.3 Others
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 CSL Limited
6.1.2 Takeda Pharmaceutical Company Limited
6.1.3 Grifols S A
6.1.4 Octapharma AG
6.1.5 Bayer AG
6.1.6 Kedrion Biopharma Inc
6.1.7 China Biologic Products Holdings Inc
6.1.8 Biotest AG
6.1.9 Annexon Inc.
6.1.10 Cellenkos inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS